| Nov 11 |
Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial
|
| Nov 5 |
Can-Fite BioPharma Secures Australian Patent for Obesity Drug
|
| Nov 4 |
Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia
|
| Oct 18 |
Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson
|
| Oct 9 |
Can-Fite stock rallies 17% on FDA orphan drug designation
|
| Oct 9 |
FDA Grants Orphan Drug Designation to Can-Fite’s Namodenoson for Pancreatic Cancer
|
| Oct 7 |
Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on October 29
|
| Sep 24 |
Can-Fite gains after agreement for animal arthritis drug
|
| Sep 24 |
Projected Income of $325M to Can-Fite Over the Next 10 Years After Vetbiolix Exercised its Option and Licensed Piclidenoson for Veterinary Osteoarthritis
|
| Sep 16 |
Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health
|
